Danaher (DHR) Expected to Announce Quarterly Earnings on Tuesday

Danaher (NYSE:DHR - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, April 22nd. Analysts expect Danaher to post earnings of $1.62 per share and revenue of $5.58 billion for the quarter. Danaher has set its FY 2025 guidance at 7.600-7.750 EPS.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Price Performance

Shares of DHR stock traded down $1.00 during mid-day trading on Thursday, hitting $195.31. 428,816 shares of the stock traded hands, compared to its average volume of 3,338,113. Danaher has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company's 50-day simple moving average is $201.21 and its 200-day simple moving average is $225.57. The firm has a market cap of $139.59 billion, a price-to-earnings ratio of 36.96, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is a positive change from Danaher's previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend is Friday, March 28th. Danaher's payout ratio is presently 24.85%.

Analysts Set New Price Targets

DHR has been the subject of several research reports. The Goldman Sachs Group reduced their price objective on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday. Guggenheim restated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday. Wells Fargo & Company dropped their price target on Danaher from $280.00 to $240.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. Stifel Nicolaus upgraded Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price on the stock in a report on Friday, March 14th. Finally, UBS Group reduced their target price on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a report on Wednesday. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $264.40.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.